Reduction of oxyradical damage in biomedical applications

Details Reduction of oxyradical damage in biomedical applications Reduction of oxyradical damage in biomedical applications

1990-07-17

1991-09-10

Waddell, Frederick E.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

514 12, 514 21, 514422, 514424, 514427, A61K 3700, A61K 3140

Patent

active

050473956

ABSTRACT:
The biliproteins delta-bilirubin and delta-bilipeptide are useful as a cytoprotective antioxidants. Delta-bilipeptide as the term is used herein is a truncated form of delta-bilirubin in which an albumin analogue of 10-200 amino acid residues replaces the albumin portion of delta-bilirubin. Patient-administrable compositions for addition to a patient's blood to minimize oxyradical damage caused by ischemia-reperfusion injury that may result in various surgical procedures, and comprising delta-bilirubin or delta-bilipeptide, are described.

REFERENCES:
patent: 4877810 (1989-10-01), Mickle et al.
Stoker et al., 1989 Biochim. Biophys. Acta 213:353-357.

Affiliated with

Also associated with

Rating

Reduction of oxyradical damage in biomedical applications does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Reduction of oxyradical damage in biomedical applications, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Reduction of oxyradical damage in biomedical applications will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-540122